ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2307

Frequency of Comorbidities in Patients with Juvenile Ideopathic Arthritis – Results of an Observational Cohort Study

Jens Klotsche1, Nadine Betenstehl2, Gerd Ganser3, Eva Seipelt4, Stefanie Tatsis5, Heike-Franziska Weidemann6, Ivan Foeldvari7, Gerd Horneff8 and Kirsten Minden9, 1Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, 2Oberhavelkliniken Hennigsdorf, Hennigsdorf, Germany, 3Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, 4Rheumatologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Germany, 5Geriatrie/Rheumatologie, Kath. Marienkrankenhaus Hamburg gGmbH, Hamburg, Germany, 6Internist.-Rheum. Praxis Dr. Weidemann, Hannover, Germany, 7Hamburger Zentrum für Kinder-und Jugend Rheumatologie, Hamburg, Germany, 8Arnold-Janssen-Strasse 29, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 9Epidemiology unit, German Rheumatism Research Center, Berlin, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Comorbidity and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often persists into adulthood. In addition to disability and poorer quality of life, JIA is associated with increased long-term morbidity and mortality. The long-term risk of comorbidities is uncertain and guidance on risk assessment is not currently available. The objective of this study was to determine the frequency of comorbid conditions in JIA patients.

Methods: Patients with JIA transferred from the biologic registry BIKER to the follow-up (FU) registry JuMBO were included in this analysis. All comorbidities, except for serious infections, prospectively recorded by physicians to BiKeR or JuMBO were considered. Comorbidity rates among the various JIA categories were assessed. The Medical Dictionary for Regulatory Activities (MedDRA) was used for disorder coding. Differences in the occurrence of comorbidities between JIA categories were analyzed by multinomial logistic regression.

Results: A total of 1,022 young adults (67% female) with JIA and a mean FU of 7.8 (SD=3.5) years (ys) were included in this analysis. The patients´ mean age was 23.1 ys (SD=3.7), and disease duration was 12.8 ys (SD=5.9) at last FU. The majority were classified as polyarticular-course JIA (53%) at BiKeR enrollment. Patients had received a mean of 2.9 (SD=1.3) DMARDs, 77% were ever treated with biologics. Comorbidities were reported for more than half of the patients (54%), 24.5% of the conditions were stated for the first time in adult age. Eye disorders were the most common comorbid condition group (16.9%), followed by Immune system disorders (12.3%), and psychiatric disorders (10.1%). The most frequently reported single diseases were uveitis in 15.9%, depression in 9.1%, hypertension in 8.5%, chronic secondary pain syndrome in 4.4%, and psoriasis in 3.3%. Females had significantly more often depression (11.8% versus 3.4%), pain syndromes (5.8% versus 1.6%), and autoimmune thyroiditis (3.3% vs. 0.9%) than males, whereas men had more often inflammatory bowel diseases than women (4.0% vs. 1.9%)). The rate of comorbid conditions significantly differed across the various JIA categories, with the highest rates in patients with extended oligoarthritis, psoriatic arthritis and systemic arthritis. While extraarticular manifestations of JIA were the most common comorbid conditions in extended oligoarthritis and psoriatic arthritis, disease- or treatment-related complications were relevant comorbidities in systemic arthritis.

Conclusion: Young adults with JIA have a high rate of comorbidity overall, with extraarticular JIA manifestations being the most frequent comorbid conditions. Comorbidity rates vary among the various JIA categories. Patients with systemic JIA have the highest rate of cardiovascular risk factors and osteoporosis, while patients with extended OA have the highest rate of uveitis. An underreporting or unawareness of comorbidities by rheumatologists is possible, guidance on risk assessment in adults with JIA is needed.


Disclosure: J. Klotsche, None; N. Betenstehl, None; G. Ganser, None; E. Seipelt, None; S. Tatsis, None; H. F. Weidemann, None; I. Foeldvari, None; G. Horneff, AbbVie, Pfizer, Novartis, and Roche, 2,AbbVie, Novartis, Sobi, Pfizer, and Roche, 9; K. Minden, Pfizer, Abbvie, Roche, 2,Pfizer, Pharm-Allergan, and Roche, 5.

To cite this abstract in AMA style:

Klotsche J, Betenstehl N, Ganser G, Seipelt E, Tatsis S, Weidemann HF, Foeldvari I, Horneff G, Minden K. Frequency of Comorbidities in Patients with Juvenile Ideopathic Arthritis – Results of an Observational Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/frequency-of-comorbidities-in-patients-with-juvenile-ideopathic-arthritis-results-of-an-observational-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-comorbidities-in-patients-with-juvenile-ideopathic-arthritis-results-of-an-observational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology